LD-2 disclosure · 3rd Quarter - Report
BAXALTA US INC.
via BAXALTA US INC.
Client
- Name
- BAXALTA US INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- BAXALTA US INC.
- Description
- Global BioPharmaceutical Company
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesCopyright/Patent/Trademark
H.R. 9, the Innovation Act: To amend title 35, United States Code, and the Leahy-Smith America Invents Act to make improvements and technical corrections, and for other purposes. S. 1137, the Protecting American Talent and Entrepreneurship Act of 2015. A bill to amend title 35, United States Code, and the Leahy-Smith America Invents Act to make improvements and technical corrections, and for other purposes.
LobbyistsJED PERRY
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars
LobbyistsJED PERRY · MARGARET NOWAK · LEO KIM
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims.
